KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Depreciation & Amortization (CF) (2017 - 2025)

Amneal Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 9 years, most recently at $49.2 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $49.2 million for Q4 2025, down 25.56% from a year ago — trailing twelve months through Dec 2025 was $223.6 million (down 5.34% YoY), and the annual figure for FY2025 was $223.6 million, down 5.34%.
  • Depreciation & Amortization (CF) for Q4 2025 was $49.2 million at Amneal Pharmaceuticals, down from $54.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for AMRX hit a ceiling of $66.1 million in Q4 2024 and a floor of $49.2 million in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $58.0 million (2022), compared with a mean of $58.1 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): rose 16.15% in 2024 and later decreased 25.56% in 2025.
  • Amneal Pharmaceuticals' Depreciation & Amortization (CF) stood at $61.2 million in 2021, then dropped by 0.21% to $61.1 million in 2022, then fell by 6.75% to $56.9 million in 2023, then increased by 16.15% to $66.1 million in 2024, then decreased by 25.56% to $49.2 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $49.2 million (Q4 2025), $54.1 million (Q3 2025), and $60.1 million (Q2 2025) per Business Quant data.